Value through Innovation27 July 2016

Clinical Study Results

  • Figopitant - Healthy
    Clinical Study Number 1157.2
    Study Indication Healthy
    Product Figopitant
    Generic Name Figopitant
    Lab Code
    Clinical Phase I
    Study Title

    A single increasing dose safety, tolerability and pharmacodynamics (citric acid challenge) study after oral administration of BIIF 1149 BS (drinking solution; single doses: 0.1 - 25 mg) in healthy male volunteers (randomised, double-blind, placebo-controlled, parallel groups)

    Study Document Trial synopsis 1157.2 english
  • Figopitant - Healthy
    Clinical Study Number 1157.3
    Study Indication Healthy
    Product Figopitant
    Generic Name Figopitant
    Lab Code
    Clinical Phase I
    Study Title

    A double-blind (within dose groups), randomised, placebo-controlled, parallel-group study to investigate the safety, tolerability and preliminary pharmacokinetics of increasing repeated oral doses (nine days treatment of 5 mg and 10 mg and eighteen days treatment of 25 mg and 40 mg) of BIIF 1149 BS in healthy male volunteers

    Study Document Trial synopsis 1157.3_CO english
  • Figopitant - Healthy
    Clinical Study Number 1157.4
    Study Indication Healthy
    Product Figopitant
    Generic Name Figopitant
    Lab Code
    Clinical Phase I
    Study Title

    A single increasing dose safety, tolerability and pharmacodynamics (citric acid challenge) study after oral administration of BIIF 1149 BS (single doses as tablets: 40, 65, 100 mg) in healthy male volunteers (randomised, double-blind within each dose group, placebo-controlled, parallel groups)

    Study Document Trial synopsis 1157.4 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.